Other than Eli Lilly, no company has been able to pose a significant challenge, at least not yet. But Novo Nordisk is also hedging ... It's no wonder the company's stock continues to beat the ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard Jørgensen is stepping down from the Danish drugmaker.

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...

Recent health updates include Texas experiencing a lull in measles cases, Omada’s successful Nasdaq debut, no bird flu ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline ... experimental obesity drugs have hit the stock hard. Shares have lost nearly 60% since ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

Earnings grew barely 14% last quarter -- and over the past year, the stock has lost roughly half its value. The board cited these "recent market challenges Novo Nordisk has been facing ...

Weight loss drugmaker Novo Nordisk (NVO ... was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...